METHOD AND SYSTEM FOR DIAGNOSIS OF NEUROPSYCHIATRIC DISORDERS INCLUDING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD), AUTISM, AND SCHIZOPHRENIA

• US 20100010336A1
• Filed: 07/23/2009
• Published: 01/14/2010
• Est. Priority Date: 02/07/2002
• Status: Abandoned Application

• Current Assignee: Jay W. Pettegrew, Kanagasabai Panchalingam
• Original Assignee: Jay W. Pettegrew, Kanagasabai Panchalingam
• Inventors: Panchalingam, Kanagasabai, PETTEGREW, Jay W.
• Application Number:
  US12/508,559
• Publication Number:
  US 20100010336A1
• Time in Patent Office: Days
• US Class Current: 600/410
• CPC Class Codes: A23L 33/175 Amino acids
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/322 having an effect on the health of the nervous system or on mental function
• CPC Class Codes: A23V 2250/0612 Carnitine
• CPC Class Codes: A61K 31/22 of acyclic acids, e.g. pravastatin
• CPC Class Codes: A61K 36/28 Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea

Abstract

A method and system for medical imaging of neuropsychiatric disorders including attention deficit hyperactivity disorder (ADHD), autism, and schizophrenia. Noninvasive, in vivo methods identify novel brain molecular biomarkers of normal neurodevelopment in order to determine molecular underpinnings of abnormal neurodevelopment. The described brain molecular biomarkers will aid in the presymptomatic diagnosis of neuropsychiatric disorders which begin in childhood and adolescence, such as ADHD, autism, and schizophrenia.

Claims

1. A method for diagnosing attention deficit hyperactivity disorder (ADHD), autism or schizophrenia disease in a human, comprising:

imaging a brain of a human with a medical imaging process, wherein the medical imaging process is a multinuclear magnetic resonance process based on comparison of intensities obtained from relevant ³¹P or ¹H nuclear magnetic resonance signals obtained from normal human child hosts and known abnormal human child hosts with cognitive impairment due to attention deficit hyperactivity disorder (ADHD), autism or schizophrenia with signal information obtained from a new human child patient with an unknown cognitive condition;

determining a first signal intensity for synaptic phosphomonoesters (sPME) of the human brain;

determining a second signal intensity for synaptic phosphodiesters (sPDE) of the human brain;

determining a third signal intensity for synaptic vesicles phosphodiesters (iPDE) of the human brain;

determining a fourth signal intensity for phosphocreatine (PCr) of the human brain;

determining a fifth signal intensity for myo-inositol of the human brain; and

determining whether a conclusion of cognitively impaired cognitive impairment due to attention deficit hyperactivity disorder (ADHD), autism or schizophrenia is suggested using the determined first, second, third, fourth and fifth signal intensities.

2. The method of claim 1 wherein an increased sPME level, a decreased sPDE level, a decreased iPDE level, a decreased PCr level and a decreased myo-inositol level antedate abnormal brain structural changes for determining attention deficit hyperactivity disorder (ADHD), autism or schizophrenia.

3. A method for diagnosing attention deficit hyperactivity disorder (ADHD), autism or schizophrenia disease in a human, comprising:

imaging a brain of a human with a medical imaging process, wherein the medical imaging process is a multinuclear magnetic resonance process based on comparison of intensities obtained from relevant ³¹P or ¹H nuclear magnetic resonance signals obtained from normal human child hosts and known abnormal human child hosts with cognitive impairment due to attention deficit hyperactivity disorder (ADHD), autism or schizophrenia with signal information obtained from a new human child patient with an unknown cognitive condition; and

determining whether a conclusion of cognitively impaired cognitive impairment due to attention deficit hyperactivity disorder (ADHD), autism or schizophrenia is suggested using a first signal intensity for synaptic phosphomonoesters (sPME) of the human brain, a second signal intensity for synaptic phosphodiesters (sPDE) of the human brain, a third signal intensity for synaptic vesicles phosphodiesters (iPDE) of the human brain, a fourth signal intensity for phosphocreatine (PCr) of the human brain, and a fifth signal intensity for myo-inositol of the human brain

4. The method of claim 3 wherein an increased sPME level, a decreased sPDE level, a decreased iPDE level, a decreased PCr level and a decreased myo-inositol level antedate abnormal brain structural changes for determining attention deficit hyperactivity disorder (ADHD), autism or schizophrenia.